All In Biotech

Drug Trial Radar · NCT06285370

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

An Open-Label, Multicenter, Single Arm Study to Evaluate the Efficacy and Safety of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

May 29, 2023

Primary completion

Aug 12, 2025

Study completion Nov 10, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Conditions

  • Cutaneous T-Cell Lymphoma

Interventions

  • MogamulizumabDrug

    Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: At the end of each cycle (each cycle is 28 days) until progression up to 29 months;

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital, Department of Dermatology and Venereology

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center, Department of Medical Oncology

    Guangzhou, Guangdong, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • ZheJiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • First Affiliated Hospital of Zhengzhou University

    Henan, Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.